MED10

Across TCGA pan-cancer cohorts, MED10 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MED10 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MED10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED10 expression acts as an unfavorable survival marker.

COAD, CESC, and LUAD are the cancer types where MED10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.181	0.806	.002	12	view →
CESC	OS	Median	II,III,IV	0.227	0.759	.029	6	view →
LUAD	OS	Median	All	0.188	0.670	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MED10–COAD (OS)

Open the COAD breakdown →